The Longer, the Better: Continuous Glucose Monitoring Use for >=90% Is Superior to 70%-89% in Achieving Tighter Glycemic Outcomes in Children with Type 1 Diabetes

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F25%3A10489650" target="_blank" >RIV/00179906:_____/25:10489650 - isvavai.cz</a>

Alternative codes found

RIV/44555601:13450/25:43899169 RIV/00216208:11110/25:10489650 RIV/00216208:11120/25:43927839 RIV/00216208:11130/25:10489650 and 6 more

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=eZGd_yIWFT" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=eZGd_yIWFT</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1089/dia.2024.0472" target="_blank" >10.1089/dia.2024.0472</a>

Result language

angličtina

Original language name

The Longer, the Better: Continuous Glucose Monitoring Use for >=90% Is Superior to 70%-89% in Achieving Tighter Glycemic Outcomes in Children with Type 1 Diabetes

Original language description

Objective: The recommended threshold for the time spent on continuous glucose monitoring (CGM) is established at 70%. However, glucose outcomes in children with type 1 diabetes (CwD) using CGM for a different proportion of time within this threshold have not been evaluated yet. The study aims to compare glycemic parameters among CwD who spent 70%-89% and &gt;=90% on CGM using the population-wide data from the Czech national pediatric diabetes registry ČENDA. Methods: CwD aged &lt;19 years who used real-time CGM &gt;70% of the time and did not change the type of therapy throughout the year 2023 were included and divided into two groups based on the time they spent on CGM-70%-89% versus &gt;=90%. HbA1c, times in standard glycemic ranges, mean glucose, and coefficient of variability (CV) were compared between the groups and by treatment modalities. Results: Data from 1977 CwD (1035 males and 942 females) were evaluated. Among them, 404 participants (20.4%) used CGM 70%-89% of the time, and 1573 participants (79.6%) &gt;=90% of the time. Compared with the 70-89% group, the &gt;=90% CGM users achieved significantly lower HbA1c levels (51 mmol/mol, 6.8% vs. 58 mmol/mol, 7.4%, P &lt; 0.001), higher time in range (72% vs. 60%, P &lt; 0.001), and lower mean glucose and CV (8.1 mmol/L, 146 mg/dL vs. 9.1 mmol/L, 164 mg/dL and 37% vs. 40%, respectively, both P &lt; 0.001). Analogous results were seen irrespective of the treatment modality. The differences persisted after propensity score adjustment. Conclusion: CGM use for &gt;=90% is associated with tighter glycemic control compared with 70%-89% use. Therefore, it is essential to motivate CwD to use CGM for the longest possible time and search for suitable options to overcome barriers in uninterrupted CGM monitoring.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30209 - Paediatrics

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2025

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Diabetes Technology &amp; Therapeutics

ISSN

1520-9156

e-ISSN

1557-8593

Volume of the periodical

27

Issue of the periodical within the volume

4

Country of publishing house

US - UNITED STATES

Number of pages

7

Pages from-to

301-307

UT code for WoS article

001390805300001

EID of the result in the Scopus database

2-s2.0-85215668137